Verrica Pharmaceuticals Inc.
VRCA Nasdaq
SEC CIK 1660334
Follow Verrica Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$6.9M
−51.8% vs same quarter last year
Net income
−$12.4M
−4428.1% vs same quarter last year
EPS, diluted
−$0.58
−1833.3% vs same quarter last year
Operating cash flow
−$9M
−193.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $35.6M | −$17.9M |
| FY24 | $7.6M | −$76.6M |
| FY23 | $5.1M | −$67M |
| FY22 | $9M | −$24.5M |
| FY21 | $12M | −$35.1M |
| FY20 | - | −$42.7M |
| FY19 | - | −$28.2M |
| FY18 | - | −$20.6M |
| FY17 | - | −$4.5M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −34.2% | −50.3% |
| FY24 | −871.3% | −1012.4% |
| FY23 | −1283.4% | −1307.6% |
| FY22 | −235.8% | −271.1% |
| FY21 | −257.6% | −292.3% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$17.6M |
| FY24 | −$61M |
| FY23 | −$38.9M |
| FY22 | −$19M |
| FY21 | −$28.5M |
| FY20 | −$31.7M |
| FY19 | −$28.1M |
| FY18 | −$18.6M |
| FY17 | - |
| FY16 | - |
- Verrica Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Verrica Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −50.3% | −30.6% |
| FY24 | −1012.4% | −47% |
| FY23 | −1307.6% | −58% |
| FY22 | −271.1% | −80.4% |
| FY21 | −292.3% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |